<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47041">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084927</url>
  </required_header>
  <id_info>
    <org_study_id>37/14</org_study_id>
    <nct_id>NCT02084927</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery</brief_title>
  <official_title>Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery -Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate, in a prospective cross-over, randomized study,
      the effect of hyperbaric oxygen therapy (HBOT) on patients with chronic neurological
      deficits and cognitive impairment after anterior skull base meningioma tumor removal.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Neurocognitive functions</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive function will be assessed using the one-hour Mindstreams Computerized Cognitive Test Battery at baseline, 3 months and 6 months to intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of live will be evaluated by the EQ-5D questionnaire at baseline , 3 months and 6 months to intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Intracranial Meningioma</condition>
  <condition>Neurologic Deficits</condition>
  <arm_group>
    <arm_group_label>HBOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group will be treated with HBOT for 60 treatments in 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Crossover</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBOT</intervention_name>
    <description>HBOT of 2 ATA for 90 minutes, for 60 treatments</description>
    <arm_group_label>HBOT</arm_group_label>
    <arm_group_label>Control/Crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post intracranial meningioma removal surgery 3-12 months prior to the inclusion in
             the study.

          -  All patients have to have persistent cognitive or neurological complaints regarding
             without noticeable improvement during the last month prior to their enrolment.

          -  Age 18 years or older.

        Exclusion Criteria:

          -  Dynamic neurologic/cognitive improvement or worsening during the past month;

               -  Evidence of dynamic cognitive/neurological improvement in the last month.

               -  Previous brain radiotherapy and/or radiosurgery.

               -  Steroids dependence

               -  Seizures 1 month previous to inclusion

               -  Had been treated with HBOT for any other reason 1 month prior to inclusion;

               -  Have any other indication for HBOT;

               -  Chest pathology incompatible with pressure changes;

               -  Inner ear disease;

               -  Patients suffering from claustrophobia;

               -  Inability to sign written informed consent;

               -  Smoking patients will not be allowed to smoke during the study and if they would
                  not comply with this demand they will be excluded.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shai Efrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Hadanny, MD</last_name>
    <phone>972544707381</phone>
    <email>amir.had@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin,</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>March 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assaf-Harofeh Medical Center</investigator_affiliation>
    <investigator_full_name>Assaf Harofeh MC</investigator_full_name>
    <investigator_title>Shai Efrati</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
